Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.080
-0.160 (-7.14%)
At close: Jun 16, 2025, 4:00 PM
2.070
-0.010 (-0.48%)
After-hours: Jun 16, 2025, 7:57 PM EDT
Iovance Biotherapeutics Stock Forecast
IOVA's stock price has decreased by -74.51% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $12.22, which forecasts a 487.5% increase in the stock price over the next year. The lowest target is $2 and the highest is $25.
Price Target: $12.22 (+487.5%)
Analyst Consensus: Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 5 | 5 | 4 | 4 |
| Buy | 3 | 4 | 2 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $17 → $2 | Strong Buy → Hold | Downgrades | $17 → $2 | -3.85% | May 16, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +284.62% | May 12, 2025 |
| Mizuho | Mizuho | Buy Maintains $30 → $10 | Buy | Maintains | $30 → $10 | +380.77% | May 12, 2025 |
| Barclays | Barclays | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +92.31% | May 12, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 9, 2025 |
Financial Forecast
Revenue This Year
306.39M
from 164.07M
Increased by 86.74%
Revenue Next Year
526.71M
from 306.39M
Increased by 71.91%
EPS This Year
-1.06
from -1.28
EPS Next Year
-0.71
from -1.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 499.0M | 762.4M | 1.2B | ||
| Avg | 306.4M | 526.7M | 735.3M | ||
| Low | 245.7M | 367.5M | 465.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 204.1% | 148.8% | 134.9% | ||
| Avg | 86.7% | 71.9% | 39.6% | ||
| Low | 49.7% | 19.9% | -11.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | 0.02 | 1.05 | ||
| Avg | -1.06 | -0.71 | 0.35 | ||
| Low | -1.39 | -1.12 | -0.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.